https://ibima.eu/en/first-in-human-open-label-phase-1-2-study-of-the-monoclonal-antibody-programmed-cell-death-protein-1-pd-1-inhibitor-cetrelimab-jnj-63723283-in-patients-with-advanced-cancers/ Sat, 01 Jan 2022 00:00:00 +0000 hourly 1 https://wordpress.org/?v=6.5.5